Dose-finding exploratory study on Azithromycin on senescence in healthy volunteers
interventional
N/A
1 country
1
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 30, 2025
Actual (reported)Primary endpoints of this pilot study will be changes in 1) senescent cell abundance in the blood cells by p16INK4A evaluation; 2) other serum markers of aging/inflammaging
To determine the minimum effective dose
To examine the safety
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Azitromicina Teva Italia 200 mg/5 ml polvere per sospensione orale
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
ORAL SUSPENSION
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Azitromicina Teva Italia 200 mg/5 ml polvere per sospensione orale
Named ingredient: Azithromycin
View registry recordAzienda Ospedaliera Di Perugia
Perugia, 06129, Italy
Alessio Nencioni
First Submitted
May 30, 2025
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.